United States Type 2 Diabetes Therapeutics Market Report & Forecast 2021-2027
Table of Contents1 Introduction to Research & Analysis Reports
1.1 Type 2 Diabetes Therapeutics Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 United States Type 2 Diabetes Therapeutics Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year
2 United States Type 2 Diabetes Therapeutics Overall Market Size
2.1 United States Type 2 Diabetes Therapeutics Market Size: 2021 VS 2027
2.2 United States Type 2 Diabetes Therapeutics Revenue, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Type 2 Diabetes Therapeutics Players in United States Market
3.2 Top United States Type 2 Diabetes Therapeutics Companies Ranked by Revenue
3.3 United States Type 2 Diabetes Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Type 2 Diabetes Therapeutics Companies in United States Market, by Revenue in 2020
3.5 Companies Type 2 Diabetes Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Type 2 Diabetes Therapeutics Players in United States Market
3.6.1 List of Tier 1 Type 2 Diabetes Therapeutics Companies in United States
3.6.2 List of Tier 2 and Tier 3 Type 2 Diabetes Therapeutics Companies in United States
4 Sights by Type
4.1 Overview
4.1.1 By Type - United States Type 2 Diabetes Therapeutics Market Size Markets, 2021 & 2027
4.1.2 DPP-4 Inhibitors
4.1.3 Biguanides
4.1.4 Insulins
4.1.5 SGLT-2 Inhibitors
4.1.6 ?-Glucosidase Inhibitors
4.1.7 Other
4.2 By Type - United States Type 2 Diabetes Therapeutics Revenue & Forecasts
4.2.1 By Type - United States Type 2 Diabetes Therapeutics Revenue, 2016-2021
4.2.2 By Type - United States Type 2 Diabetes Therapeutics Revenue, 2022-2027
4.2.3 By Type - United States Type 2 Diabetes Therapeutics Revenue Market Share, 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - United States Type 2 Diabetes Therapeutics Market Size, 2021 & 2027
5.1.2 Children
5.1.3 Middle-Aged Person
5.1.4 Aged
5.2 By Application - United States Type 2 Diabetes Therapeutics Revenue & Forecasts
5.2.1 By Application - United States Type 2 Diabetes Therapeutics Revenue, 2016-2021
5.2.2 By Application - United States Type 2 Diabetes Therapeutics Revenue, 2022-2027
5.2.3 By Application - United States Type 2 Diabetes Therapeutics Revenue Market Share, 2016-2027
6 Type 2 Diabetes Therapeutics Companies Profiles
6.1 AstraZeneca
6.1.1 AstraZeneca Company Details
6.1.2 AstraZeneca Business Overview
6.1.3 AstraZeneca Type 2 Diabetes Therapeutics Introduction
6.1.4 AstraZeneca Type 2 Diabetes Therapeutics Revenue in United States Market (2016-2021)
6.1.5 AstraZeneca Recent Developments
6.2 Novartis
6.2.1 Novartis Company Details
6.2.2 Novartis Business Overview
6.2.3 Novartis Type 2 Diabetes Therapeutics Introduction
6.2.4 Novartis Type 2 Diabetes Therapeutics Revenue in United States Market (2016-2021)
6.2.5 Novartis Recent Developments
6.3 Novo Nordisk
6.3.1 Novo Nordisk Company Details
6.3.2 Novo Nordisk Business Overview
6.3.3 Novo Nordisk Type 2 Diabetes Therapeutics Introduction
6.3.4 Novo Nordisk Type 2 Diabetes Therapeutics Revenue in United States Market (2016-2021)
6.3.5 Novo Nordisk Recent Developments
6.4 Boehringer Ingelheim
6.4.1 Boehringer Ingelheim Company Details
6.4.2 Boehringer Ingelheim Business Overview
6.4.3 Boehringer Ingelheim Type 2 Diabetes Therapeutics Introduction
6.4.4 Boehringer Ingelheim Type 2 Diabetes Therapeutics Revenue in United States Market (2016-2021)
6.4.5 Boehringer Ingelheim Recent Developments
6.5 Bristol-Myers Squibb
6.5.1 Bristol-Myers Squibb Company Details
6.5.2 Bristol-Myers Squibb Business Overview
6.5.3 Bristol-Myers Squibb Type 2 Diabetes Therapeutics Introduction
6.5.4 Bristol-Myers Squibb Type 2 Diabetes Therapeutics Revenue in United States Market (2016-2021)
6.5.5 Bristol-Myers Squibb Recent Developments
6.6 Eli Lilly
6.6.1 Eli Lilly Company Details
6.6.2 Eli Lilly Business Overview
6.6.3 Eli Lilly Type 2 Diabetes Therapeutics Introduction
6.6.4 Eli Lilly Type 2 Diabetes Therapeutics Revenue in United States Market (2016-2021)
6.6.5 Eli Lilly Recent Developments
6.7 Merck
6.7.1 Merck Company Details
6.7.2 Merck Business Overview
6.7.3 Merck Type 2 Diabetes Therapeutics Introduction
6.7.4 Merck Type 2 Diabetes Therapeutics Revenue in United States Market (2016-2021)
6.7.5 Merck Recent Developments
6.8 Sanofi
6.8.1 Sanofi Company Details
6.8.2 Sanofi Business Overview
6.8.3 Sanofi Type 2 Diabetes Therapeutics Introduction
6.8.4 Sanofi Type 2 Diabetes Therapeutics Revenue in United States Market (2016-2021)
6.8.5 Sanofi Recent Developments
7 Conclusion
8 Appendix
8.1 Note
8.2 Examples of Clients
8.3 Author Details
8.4 Disclaimer
List of TablesTable 1. Type 2 Diabetes Therapeutics Market Opportunities & Trends in United States Market
Table 2. Type 2 Diabetes Therapeutics Market Drivers in United States Market
Table 3. Type 2 Diabetes Therapeutics Market Restraints in United States Market
Table 4. Key Players of Type 2 Diabetes Therapeutics in United States Market
Table 5. Top Type 2 Diabetes Therapeutics Players in United States Market, Ranking by Revenue (2019)
Table 6. United States Type 2 Diabetes Therapeutics Revenue by Companies, (US$, Mn), 2016-2021
Table 7. United States Type 2 Diabetes Therapeutics Revenue Share by Companies, 2016-2021
Table 8. Companies Type 2 Diabetes Therapeutics Product Type
Table 9. List of Tier 1 Type 2 Diabetes Therapeutics Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Tier 2 and Tier 3 Type 2 Diabetes Therapeutics Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type - United States Type 2 Diabetes Therapeutics Revenue, (US$, Mn), 2021 & 2027
Table 12. By Type - United States Type 2 Diabetes Therapeutics Revenue (US$, Mn), 2016-2021
Table 13. By Type - United States Type 2 Diabetes Therapeutics Revenue (US$, Mn), 2022-2027
Table 14. By Application - United States Type 2 Diabetes Therapeutics Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - United States Type 2 Diabetes Therapeutics Revenue (US$, Mn), 2016-2021
Table 16. By Application - United States Type 2 Diabetes Therapeutics Revenue (US$, Mn), 2022-2027
Table 17. AstraZeneca Company Details
Table 18. AstraZeneca Business Overview
Table 19. AstraZeneca Type 2 Diabetes Therapeutics Product
Table 20. AstraZeneca Type 2 Diabetes Therapeutics Revenue in United States Market (2016-2021) & (US$ Million)
Table 21. AstraZeneca Recent Developments
Table 22. Novartis Company Details
Table 23. Novartis Business Overview
Table 24. Novartis Type 2 Diabetes Therapeutics Product
Table 25. Novartis Type 2 Diabetes Therapeutics Revenue in United States Market (2016-2021) & (US$ Million)
Table 26. Novartis Recent Developments
Table 27. Novo Nordisk Company Details
Table 28. Novo Nordisk Business Overview
Table 29. Novo Nordisk Type 2 Diabetes Therapeutics Product
Table 30. Novo Nordisk Type 2 Diabetes Therapeutics Revenue in United States Market (2016-2021) & (US$ Million)
Table 31. Novo Nordisk Recent Developments
Table 32. Boehringer Ingelheim Company Details
Table 33. Boehringer Ingelheim Business Overview
Table 34. Boehringer Ingelheim Type 2 Diabetes Therapeutics Product
Table 35. Boehringer Ingelheim Type 2 Diabetes Therapeutics Revenue in United States Market (2016-2021) & (US$ Million)
Table 36. Boehringer Ingelheim Recent Developments
Table 37. Bristol-Myers Squibb Company Details
Table 38. Bristol-Myers Squibb Business Overview
Table 39. Bristol-Myers Squibb Type 2 Diabetes Therapeutics Product
Table 40. Bristol-Myers Squibb Type 2 Diabetes Therapeutics Revenue in United States Market (2016-2021) & (US$ Million)
Table 41. Bristol-Myers Squibb Recent Developments
Table 42. Eli Lilly Company Details
Table 43. Eli Lilly Business Overview
Table 44. Eli Lilly Type 2 Diabetes Therapeutics Product
Table 45. Eli Lilly Type 2 Diabetes Therapeutics Revenue in United States Market (2016-2021) & (US$ Million)
Table 46. Eli Lilly Recent Developments
Table 47. Merck Company Details
Table 48. Merck Business Overview
Table 49. Merck Type 2 Diabetes Therapeutics Product
Table 50. Merck Type 2 Diabetes Therapeutics Revenue in United States Market (2016-2021) & (US$ Million)
Table 51. Merck Recent Developments
Table 52. Sanofi Company Details
Table 53. Sanofi Business Overview
Table 54. Sanofi Type 2 Diabetes Therapeutics Product
Table 55. Sanofi Type 2 Diabetes Therapeutics Revenue in United States Market (2016-2021) & (US$ Million)
Table 56. Sanofi Recent Developments
List of FiguresFigure 1. Type 2 Diabetes Therapeutics Segment by Type
Figure 2. Type 2 Diabetes Therapeutics Segment by Application
Figure 3. United States Type 2 Diabetes Therapeutics Market Overview: 2020
Figure 4. United States Type 2 Diabetes Therapeutics Market Size: 2021 VS 2027 (US$, Mn)
Figure 5. United States Type 2 Diabetes Therapeutics Revenue, 2016-2027 (US$, Mn)
Figure 6. The Top 3 and 5 Players Market Share by Type 2 Diabetes Therapeutics Revenue in 2020
Figure 7. By Type - United States Type 2 Diabetes Therapeutics Revenue Market Share, 2016-2027
Figure 8. By Application - United States Type 2 Diabetes Therapeutics Revenue Market Share, 2016-2027
Figure 9. AstraZeneca Type 2 Diabetes Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 10. Novartis Type 2 Diabetes Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 11. Novo Nordisk Type 2 Diabetes Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 12. Boehringer Ingelheim Type 2 Diabetes Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 13. Bristol-Myers Squibb Type 2 Diabetes Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 14. Eli Lilly Type 2 Diabetes Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 15. Merck Type 2 Diabetes Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 16. Sanofi Type 2 Diabetes Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2016-2021)